Ibrutinib and Venetoclax for First-Line Treatment of CLLNitin Jain, William G. Wierda, Koji Sasaki et al.|New England Journal of Medicine|2019Cited by 502
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trialsTimothy A. Yap, Marina Konopleva, Naval Daver et al.|Nature Medicine|2023Cited by 372
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid LeukemiaCourtney D. DiNardo, Hagop M. Kantarjian, Curtis A. Lachowiez et al.|Journal of Clinical Oncology|2021Cited by 333
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trialCourtney D. DiNardo, Marina Konopleva, Abhishek Maiti et al.|The Lancet Haematology|2020Cited by 330
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trialsKoji Sasaki, Jörge E. Cortes, Sara S. Strom et al.|The Lancet Haematology|2015Cited by 313